Needham Maintains Buy on OncoCyte, Raises Price Target to $4.25
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson maintains a Buy rating on OncoCyte (NASDAQ:OCX) and raises the price target from $3.6 to $4.25, indicating a positive outlook on the stock.
April 24, 2024 | 6:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Mike Matson maintains a Buy rating on OncoCyte and raises the price target from $3.6 to $4.25.
The increase in price target by a reputable analyst suggests a strong confidence in OncoCyte's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100